Video: Stephen Smith, CEO of NOCD, talks about the increase of OCD therapy sessions since the outbreak of COVID-19 […]
Cyclacel Pharmaceuticals Inc., a Berkeley Heights-based biopharmaceutical company, has entered into an agreement with the University of Edinburgh to study its clinical stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. The partners will assess the suitability of Cyclacel’s medicines for use in safety and experimental studies. […]
Stem cells haven’t exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant. There are at least a few […]